Novavax Statement on Stock Trading Halt; FDA Advisory Committee to Review Novavax’ COVID-19 Vaccine

June 7, 2022

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that NASDAQ has halted trading of the company’s common stock.

The U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) is meeting today to review NVX-CoV2373 COVID-19 Vaccine (recombinant, adjuvanted) for active immunization against SARS-CoV-2 in individuals 18 years of age and over.

The Advisory Committee meeting is scheduled for 8:30AM ET. The briefing materials can be found on the FDA website.

The VRBPAC reviews and evaluates data regarding the safety and efficacy of vaccines and related biological products that are intended for use in the prevention, treatment, or diagnosis of human diseases.